Gene · 970
CD70: CD70 molecule
11 sourcesgene-search-2026-11-11-0.1.0
Cite this record
ConductScience Library. CD70: CD70 molecule. Genes, record 970. Release gene-search-2026-11-11-0.1.0, 11 Nov 2026. https://conductscience.org/library/genes/970
On this page
Gene
Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P32970 | CD70 antigen | 193 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents411
Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4801963 A1 | 2026-09-09 | 143 | P32970 | Espacenet |
| EP 4796562 A1 | 2026-08-26 | 104 | P32970 | Espacenet |
| JP 2026086743 A | 2026-05-26 | 172 | P32970 | Espacenet |
| US 12636345 B2 | 2026-05-26 | 32 | P32970 | Espacenet |
| JP 2026516158 A | 2026-05-19 | 3 | P32970 | Espacenet |
| JP 2026062687 A | 2026-04-10 | 139 | P32970 | Espacenet |
| EP 4722370 A1 | 2026-04-08 | 23 | P32970 | Espacenet |
| EP 4709396 A1 | 2026-03-18 | 3 | P32970 | Espacenet |
| EP 4705273 A2 | 2026-03-11 | 330 | P32970 | Espacenet |
| JP 2026000897 A | 2026-01-06 | 335 | P32970 | Espacenet |
1 to 10 of 411
See all 411 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CUSATUZUMAB | CHEMBL4297891 | CD70 antigen inhibitor | INHIBITOR | ChEMBL |
| MDX-1411 | CHEMBL2109492 | CD70 antigen cross-linking agent | CROSS-LINKING AGENT | ChEMBL |
| VORSETUZUMAB | CHEMBL2108673 | CD70 antigen binding agent | BINDING AGENT | ChEMBL |
| VORSETUZUMAB MAFODOTIN | CHEMBL2108672 | CD70 antigen binding agent | BINDING AGENT | ChEMBL |
Trials12
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06384261 | CUSATUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT04264806 | CUSATUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT04241549 | CUSATUZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT04150887 | CUSATUZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT04023526 | CUSATUZUMAB | PHASE2 | 2024-07-30 | ClinicalTrials.gov |
| NCT03030612 | CUSATUZUMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT02759250 | CUSATUZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT01813539 | CUSATUZUMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT01677390 | VORSETUZUMAB MAFODOTIN | PHASE1 | ClinicalTrials.gov | |
| NCT01015911 | VORSETUZUMAB MAFODOTIN | PHASE1 | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsNIH grants2,135
NIH projects whose papers are about the gene, through NIH's grant-paper links.
| Project | Title | Its papers about the gene | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 31 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 30 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 16 | 2025 |
| P50CA126752 | SPORE in Lymphoma | 14 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 10 | 2025 |
| UL1TR001866 | Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success | 9 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 6 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 6 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 6 | 2025 |
| R01AI049954 | Gene Transcription in SLE | 6 | 2025 |
1 to 10 of 2,135Source NIH's project files
See all 2,135 nih grantsPapers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| PMID | Found by | Source |
|---|---|---|
| 42818546 | PubTator, text mining | PubMed |
| 42817846 | PubTator, text mining | PubMed |
| 42817840 | PubTator, text mining | PubMed |
| 42812140 | PubTator, text mining | PubMed |
| 42809589 | PubTator, text mining | PubMed |
| 42800662 | PubTator, text mining | PubMed |
| 42780029 | PubTator, text mining | PubMed |
| 42778210 | PubTator, text mining | PubMed |
| 42738247 | PubTator, text mining | PubMed |
| 42718816 | PubTator, text mining | PubMed |
1 to 10 of 4,349
See all 4,349 papersSources 11
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNone stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GeneNone named. Public domain as US government information
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/970
GET https://conductscience.org/api/genes/v1/970/patents?page=2